Integrin αvβ3‐targeted cancer therapy
- 1 September 2008
- journal article
- review article
- Published by Wiley in Drug Development Research
- Vol. 69 (6), 329-339
- https://doi.org/10.1002/ddr.20265
Abstract
Anti‐angiogenesis is a promising strategy for the treatment of cancer. Integrins, consisting of two noncovalently bound transmembrane α and β subunits, are an important molecular family involved in tumor angiogenesis. The blockade of integrin signaling has been demonstrated to be efficient to inhibit tumor growth, angiogenesis, and metastasis. Among all the integrins, αvβ3 seems to be the most important one during tumor angiogenesis. The inhibition of integrin αvβ3 signaling with antibodies, peptides, peptidomimetics, and other antagonists has great potential in the treatment of cancer. In addition, integrin αvβ3 is highly expressed on activated endothelial cells, new‐born vessels as well as some tumor cells, but is not present in resting endothelial cells and most normal organ systems, making it a suitable target for anti‐angiogenic therapy. In this article we will review the role of integrin αvβ3 in angiogenesis, present recent progress in the use of integrin αvβ3 antagonists and integrin‐targeted delivery systems as potential cancer therapeutics, and discuss future perspectives. Drug Dev Res 69:329–339, 2008.Keywords
This publication has 92 references indexed in Scilit:
- Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma MultiformeClinical Cancer Research, 2008
- Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012Journal of Clinical Oncology, 2008
- Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumorsInvestigational New Drugs, 2007
- Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumorsAnnals of Oncology, 2007
- Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumoursBritish Journal of Cancer, 2006
- Inhibition of αvβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of RadiotherapyClinical Cancer Research, 2005
- Integrin signalling during tumour progressionNature Reviews Molecular Cell Biology, 2004
- Integrins: Bidirectional, Allosteric Signaling MachinesCell, 2002
- Angiogenesis as a biomarker and target in cancer chemopreventionThe Lancet Oncology, 2001
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971